Collegium Pharmaceutical, Inc.
COLL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $631,449 | $566,767 | $463,933 | $276,868 |
| % Growth | 11.4% | 22.2% | 67.6% | – |
| Cost of Goods Sold | $254,105 | $240,598 | $254,445 | $126,251 |
| Gross Profit | $377,344 | $326,169 | $209,488 | $150,617 |
| % Margin | 59.8% | 57.5% | 45.2% | 54.4% |
| R&D Expenses | $0 | $0 | $3,983 | $9,451 |
| G&A Expenses | $172,320 | $0 | $0 | $0 |
| SG&A Expenses | $182,983 | $159,208 | $172,186 | $118,960 |
| Sales & Mktg Exp. | $10,663 | $0 | $0 | $0 |
| Other Operating Expenses | $24,466 | $0 | $0 | $4,578 |
| Operating Expenses | $207,449 | $159,208 | $176,169 | $132,989 |
| Operating Income | $169,895 | $166,961 | $33,319 | $17,628 |
| % Margin | 26.9% | 29.5% | 7.2% | 6.4% |
| Other Income/Exp. Net | -$71,327 | -$91,228 | -$62,166 | -$21,002 |
| Pre-Tax Income | $98,568 | $75,733 | -$28,847 | -$3,374 |
| Tax Expense | $29,378 | $27,578 | -$3,845 | -$74,891 |
| Net Income | $69,190 | $48,155 | -$25,002 | $71,517 |
| % Margin | 11% | 8.5% | -5.4% | 25.8% |
| EPS | 2.14 | 1.6 | -0.74 | 2.05 |
| % Growth | 33.8% | 316.2% | -136.1% | – |
| EPS Diluted | 1.86 | 1.29 | -0.74 | 1.86 |
| Weighted Avg Shares Out | 32,274 | 33,741 | 33,829 | 34,937 |
| Weighted Avg Shares Out Dil | 40,424 | 41,788 | 33,829 | 41,046 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13,976 | $15,615 | $1,047 | $12 |
| Interest Expense | $73,974 | $83,339 | $63,213 | $21,014 |
| Depreciation & Amortization | $169,160 | $149,256 | $138,939 | $68,917 |
| EBITDA | $341,702 | $308,328 | $173,305 | $86,557 |
| % Margin | 54.1% | 54.4% | 37.4% | 31.3% |